A phase 1 trial of the histone deacetylase inhibitor AR-42 in patients with neurofibromatosis type 2-associated tumors and advanced solid malignancies.
Katharine A CollierHugo ValenciaHerbert NewtonErinn M HadeDouglas W SborovRobert CavaliereMing J PoiMitch A PhelpsSophia G LivaChristopher C CossJiang WangSoun KhounthamPaul MonkCharles L ShapiroRichard L PiekarzCraig C HofmeisterD Bradley WellingAmir MortazaviPublished in: Cancer chemotherapy and pharmacology (2021)
NCT01129193, registered 5/24/2010.
Keyphrases